Erode, India

Nagarajan Muthukaman


 

 

Average Co-Inventor Count = 4.5

ph-index = 2

Forward Citations = 14(Granted Patents)


Location History:

  • Tamil Nadu, IN (2018 - 2019)
  • Erode, IN (2013 - 2020)

Company Filing History:


Years Active: 2013-2020

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Innovations by Nagarajan Muthukaman: A Focus on mPGES-1 Inhibitors

Introduction

Nagarajan Muthukaman is an esteemed inventor based in Erode, India, known for his significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 8 patents, he has made strides in developing innovative compounds aimed at addressing pain and inflammation.

Latest Patents

Muthukaman's latest patents highlight his research on triazolone compounds specifically designed as mPGES-1 inhibitors. His first patent discusses compounds of formula (I) that act as inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme, which are instrumental in treating various conditions such as asthma, osteoarthritis, rheumatoid arthritis, and neurodegenerative diseases. Another notable patent details the solid-state forms of a particular triazolone compound, namely N-(4-chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)benzyl)pivalamide (Compound of formula II), along with the processes for its preparation.

Career Highlights

Throughout his career, Muthukaman has worked with prominent companies in the pharmaceutical sector. Notably, he has contributed to the success of Glenmark Pharmaceuticals and Ichnos Sciences. His role in these organizations has helped propel innovation in drug development, particularly in addressing critical health issues.

Collaborations

Muthukaman has collaborated with notable coworkers such as Laxmikant Atmaram Gharat and Neelima Khairatkar-Joshi. These partnerships have fostered an environment of creativity and shared expertise, essential for advancing research and development within the pharmaceutical field.

Conclusion

Nagarajan Muthukaman's dedication to innovation and his extensive patent portfolio reflect his commitment to improving patient outcomes through the development of advanced pharmaceutical solutions. His contributions in the realm of mPGES-1 inhibitors will undoubtedly have a lasting impact on the treatment of various diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…